Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review
- Ralph Blumhardt1,
- Ely A Wolin1,2⇑,
- William T Phillips1,
- Umber A Salman1,
- Ronald C Walker3,4,
- Brendan C Stack Jr5 and
- Darlene Metter1
- 1University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
2San Antonio Military Medical Center, San Antonio, Texas, USA
3Tennessee Valley VA Healthcare System, Nashville, Tennessee, USA
4Vanderbilt University Medical Center, Nashville, Tennessee, USA
5UAMS Thyroid Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
- Correspondence should be addressed to E A Wolin; Emails: ely.wolin{at}us.af.mil or lewolin{at}hotmail.com
-
Figure 1
The relationship between thyroid cancer mortality and radioactive iodine ablation. Reprinted from Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97 418–428, with permission from Elsevier.
-
Figure 2
The relationship between thyroid cancer recurrence/mortality and tumor size. Reprinted from Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97 418–428, with permission from Elsevier.
- © 2014 Society for Endocrinology
